nelfinavir has been researched along with telaprevir in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Chang, SY; Chang, YH; Chen, YT; Hsu, NY; Hsu, YC; Huang, CH; Kang, JJ; Kuo, CJ; Liang, PH; Pathak, N; Tsai, HP; Yang, JM | 1 |
3 other study(ies) available for nelfinavir and telaprevir
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Uncovering Flexible Active Site Conformations of SARS-CoV-2 3CL Proteases through Protease Pharmacophore Clusters and COVID-19 Drug Repurposing.
Topics: Animals; Antiviral Agents; Catalytic Domain; Chlorocebus aethiops; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Inhibitory Concentration 50; Nelfinavir; Oligopeptides; Protease Inhibitors; Protein Conformation; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Vero Cells | 2021 |